186 related articles for article (PubMed ID: 32679555)
1. The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas.
Hahn AW; Agarwal N
Cancer Treat Res Commun; 2020; 24():100190. PubMed ID: 32679555
[No Abstract] [Full Text] [Related]
2. PARP inhibitors in castration-resistant prostate cancer.
Tripathi A; Balakrishna P; Agarwal N
Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant PARPi for urothelial carcinoma: between lifeline and desperation.
Tayeh GA; Alkassis M; Semaan A; Khalil N; Nemr E; Waked C
Future Oncol; 2021 Sep; 17(25):3281-3283. PubMed ID: 34287018
[No Abstract] [Full Text] [Related]
4. Immunotherapy for genitourinary tumors.
Nakayama T; Kitano S
Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
[TBL] [Abstract][Full Text] [Related]
5. Switch maintenance therapy for advanced bladder cancer: A paradigm shift in 2020.
Chawla NS; Malhotra J; Pal SK
Cancer Treat Res Commun; 2020; 24():100202. PubMed ID: 32805533
[No Abstract] [Full Text] [Related]
6. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
7. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.
Di Nunno V; Cimadamore A; Santoni M; Scarpelli M; Fiorentino M; Ciccarese C; Iacovelli R; Cheng L; Lopez-Beltran A; Massari F; Montironi R
Future Oncol; 2018 Oct; 14(25):2559-2564. PubMed ID: 30141348
[No Abstract] [Full Text] [Related]
8. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
Fujimoto N; Harada K; Shiota M; Tomisaki I; Minato A; Nagata Y; Kimuro R; Harada M; Fujisawa M
Anticancer Res; 2021 Oct; 41(10):4687-4695. PubMed ID: 34593416
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibition in castration-resistant prostate cancer.
Nappi L; Gleave ME
Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
[No Abstract] [Full Text] [Related]
11. Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas.
Ito K
Int J Urol; 2019 Sep; 26(9):868-877. PubMed ID: 31183903
[TBL] [Abstract][Full Text] [Related]
12. CMV chemotherapy for advanced transitional cell carcinoma.
Jeffery GM; Mead GM
Br J Cancer; 1992 Sep; 66(3):542-6. PubMed ID: 1520591
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab plus ipilimumab in advanced renal-cell carcinoma.
Gunjur A
Lancet Oncol; 2018 May; 19(5):e232. PubMed ID: 29606588
[No Abstract] [Full Text] [Related]
14. Editorial comment on: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
Malats N; Real FX
Eur Urol; 2009 Mar; 55(3):658. PubMed ID: 18584942
[No Abstract] [Full Text] [Related]
15. Editorial comment on: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
Burger M
Eur Urol; 2009 Mar; 55(3):657. PubMed ID: 18584941
[No Abstract] [Full Text] [Related]
16. Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
Ledermann JA
Gynecol Oncol; 2019 May; 153(2):213-214. PubMed ID: 31027611
[No Abstract] [Full Text] [Related]
17. M-VAC chemotherapy in the management of locally advanced bladder cancer.
Skinner DG
J Urol; 1988 Mar; 139(3):570. PubMed ID: 3343745
[No Abstract] [Full Text] [Related]
18. Significant advances in chemotherapy for both urothelial and renal cancer.
BJU Int; 2024 Feb; 133(2):122-123. PubMed ID: 38232742
[No Abstract] [Full Text] [Related]
19. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.
Lin E; Liu X; Liu Y; Zhang Z; Xie L; Tian K; Liu J; Yu Y
Front Immunol; 2021; 12():653358. PubMed ID: 33746989
[TBL] [Abstract][Full Text] [Related]
20. Genetic aberrations of homologous recombination repair pathways in prostate cancer: The prognostic and therapeutic implications.
Saeidi H; Bakrin IH; Raju CS; Ismail P; Saraf M; Khairul-Asri MG
Adv Med Sci; 2023 Sep; 68(2):359-365. PubMed ID: 37757663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
